Jeremy A. Slivnick, MD

Assistant professor of medicine in the cardiology section of the University of Chicago Medical Center   

Cardiac amyloidosis and hypertrophic cardiomyopathy share a common diagnostic problem: They are both frequently missed or mischaracterized, often for years, before the correct diagnosis reshapes a patient’s entire treatment trajectory. Dr. Slivnick has made closing that diagnostic gap his scientific mission. 

Jeremy is an academic cardiovascular imaging specialist whose research applies machine learning and multimodality imaging to the detection and subtype differentiation of cardiomyopathies. His work earned him the Arthur Weyman Young Investigator Award from the American Society of Echocardiography. This is the society’s most prestigious recognition for emerging research talent; it’s named after the physician who transformed echocardiography into a scientific discipline. 

Additionally, Dr. Slivnick directs the development of multisite, international patient registries for cardiac amyloidosis and HCM, building the kind of foundational research infrastructure that generates datasets, informs guidelines and advances diagnostic algorithms across the field. He serves on three ASE steering committees, contributes regularly to ASE scientific sessions as a presenter and abstract reviewer, and was selected for ASE’s competitive Leadership Academy. His mentor there, Dr. Federico Asch, has described him as “highly collaborative, intellectually sharp and possessed of an extremely strong work ethic.”  

At 39, Dr. Jeremy Slivnick is the kind of physician-scientist who builds the infrastructure the rest of the field will eventually rely on, and he does so quietly, rigorously and ahead of schedule.